‘This is too complex not to be done well’: Leading doctor’s message after PBS lists ketamine treatment for severe depression
The Royal Australian and New Zealand College of Psychiatrists has published updated guidance on ketamine for treatment-resistant depression.
The use of ketamine in psychiatric practice has reached an inflection point.
After decades of cautious exploration and small clinics offering off-label racemic ketamine, in April, the PBS listed ketamine-derived nasal spray esketamine (Spravato) for treatment-resistant depression.
It triggered the Royal Australian and New Zealand College of Psychiatrists to update their guidelines for the therapy.
One of the guidelines’ authors, Professor Colleen Loo, tells AusDoc it is time to sit up and pay attention.
